CA3198579A1 - Anti-marco antibodies and uses thereof - Google Patents

Anti-marco antibodies and uses thereof

Info

Publication number
CA3198579A1
CA3198579A1 CA3198579A CA3198579A CA3198579A1 CA 3198579 A1 CA3198579 A1 CA 3198579A1 CA 3198579 A CA3198579 A CA 3198579A CA 3198579 A CA3198579 A CA 3198579A CA 3198579 A1 CA3198579 A1 CA 3198579A1
Authority
CA
Canada
Prior art keywords
antibody
sequence
seq
cdr
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3198579A
Other languages
English (en)
French (fr)
Inventor
Nadine JAHCHAN
Michel Streuli
Xi Yang
Linda Liang
Venkataraman SRIRAM
Joshua Pollack
Vladislava Juric
Linnea Haeggblom
Kara Mojica
Leonard G. Presta
Sayantan Mitra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pionyr Immunotherapeutics Inc
Original Assignee
Pionyr Immunotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pionyr Immunotherapeutics Inc filed Critical Pionyr Immunotherapeutics Inc
Publication of CA3198579A1 publication Critical patent/CA3198579A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00—Arrangements affording multiple use of the transmission path
    • H04L5/003—Arrangements for allocating sub-channels of the transmission path
    • H04L5/0044—Allocation of payload; Allocation of data channels, e.g. PDSCH or PUSCH
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W28/00—Network traffic management; Network resource management
    • H04W28/02—Traffic management, e.g. flow control or congestion control
    • H04W28/08—Load balancing or load distribution
    • H04W28/082—Load balancing or load distribution among bearers or channels
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W74/00—Wireless channel access
    • H04W74/08—Non-scheduled access, e.g. ALOHA
    • H04W74/0833—Random access procedures, e.g. with 4-step access
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3198579A 2020-11-18 2021-11-18 Anti-marco antibodies and uses thereof Pending CA3198579A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063115272P 2020-11-18 2020-11-18
US63/115,272 2020-11-18
US202163244662P 2021-09-15 2021-09-15
US63/244,662 2021-09-15
PCT/US2021/059955 WO2022109178A1 (en) 2020-11-18 2021-11-18 Anti-marco antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CA3198579A1 true CA3198579A1 (en) 2022-05-27

Family

ID=81588283

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3198579A Pending CA3198579A1 (en) 2020-11-18 2021-11-18 Anti-marco antibodies and uses thereof

Country Status (10)

Country Link
US (3) US11572407B2 (cg-RX-API-DMAC7.html)
EP (1) EP4247419A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023549555A (cg-RX-API-DMAC7.html)
KR (1) KR20230121759A (cg-RX-API-DMAC7.html)
AU (1) AU2021382658A1 (cg-RX-API-DMAC7.html)
CA (1) CA3198579A1 (cg-RX-API-DMAC7.html)
IL (1) IL302874A (cg-RX-API-DMAC7.html)
MX (1) MX2023005841A (cg-RX-API-DMAC7.html)
TW (1) TW202237648A (cg-RX-API-DMAC7.html)
WO (1) WO2022109178A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202237648A (zh) 2020-11-18 2022-10-01 美商開拓免疫醫療公司 抗marco抗體及其用途
US20250011410A1 (en) * 2021-11-23 2025-01-09 Invetx, Inc. Anti-ngf antibodies and uses thereof
US20260008844A1 (en) * 2022-09-15 2026-01-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Use of anti-marco antibody with a checkpoint blockade antibody for the treatment of cancer
US20260126450A1 (en) * 2022-10-12 2026-05-07 Massachusetts Institute Of Technology Library-scale methods for polypeptide functional analysis
WO2025102054A1 (en) * 2023-11-09 2025-05-15 Massachusetts Institute Of Technology Methods of screening for secreted functional molecules

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916766A (en) 1996-05-23 1999-06-29 Smithkline Beecham Corporation Human marco scavenger receptor
US20060257359A1 (en) 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
US20100227415A1 (en) 2007-07-24 2010-09-09 Iss Immune System Stimulation Ab Method and means for prediction of systemic lupus erythematosus susceptibility
US8597946B2 (en) 2008-03-10 2013-12-03 H. Lee Moffitt Caner Center and Research Institute, Inc. Enhanced dendritic cells for cancer immunotherapy
KR20130108295A (ko) * 2010-08-13 2013-10-02 베일러 리서치 인스티튜트 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제
WO2012122396A1 (en) 2011-03-08 2012-09-13 Baylor Research Institute Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
WO2016196612A1 (en) 2015-06-01 2016-12-08 The Rockefeller University Anti-tumor agents and methods of use
WO2017062363A1 (en) 2015-10-05 2017-04-13 Joslin Diabetes Center Methods of use of betatrophin
CA3049791A1 (en) 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
EP3612563A1 (en) 2017-04-19 2020-02-26 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
TW201904588A (zh) 2017-06-25 2019-02-01 美商西雅圖免疫公司 引導及導航控制蛋白質之製造及使用方法
EP3668899A4 (en) 2017-08-18 2020-09-02 Celdara Medical, LLC CELL-BASED THERAPIES TARGETING DISEASE-ASSOCIATED MOLECULAR MEDIATORS OF FIBROTIC, INFLAMMATORY AND AUTOIMMUNE DISEASES
PL3688155T3 (pl) 2017-09-28 2023-09-11 Immpact-Bio Ltd. Uniwersalna platforma do wytwarzania hamującego chimerycznego receptora antygenowego (icar)
MX2020006654A (es) 2017-12-22 2020-11-06 Atossa Therapeutics Inc Métodos intraductales de tratamiento de trastornos de mama.
MX387358B (es) 2018-02-28 2025-03-18 Pfizer Variantes de il-15 y usos de las mismas
BR112021006100A2 (pt) 2018-09-28 2021-07-20 Immpact-Bio Ltd. métodos para identificação de pares de receptor de antígeno ativador (acar)/receptor de antígeno quimérico inibitório (icar) para uso em terapias de câncer
JP2022514215A (ja) * 2018-12-05 2022-02-10 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ Rankアンタゴニストおよびその使用
EP3906055A4 (en) 2019-01-04 2023-01-04 Trio Pharmaceuticals, Inc. MULTISPECIFIC PROTEIN MOLECULES AND THEIR USES
WO2020162696A1 (ko) 2019-02-08 2020-08-13 주식회사 굳티셀 암 치료를 위한 t 세포의 활성화 방법
US20220152148A1 (en) 2019-03-18 2022-05-19 The Broad Institute, Inc. Modulation of type 2 immunity by targeting clec-2 signaling
IL287801A (en) 2019-05-07 2022-07-01 Immunicom Inc Increasing responses to checkpoint inhibitors by extracorporeal apheresis
GB2603044B (en) 2019-06-11 2024-08-21 Myeloid Therapeutics Inc Macrophage specific engager compositions and methods of use thereof
KR20220054305A (ko) 2019-07-31 2022-05-02 온코어 파마, 인크. 면역 회피성 종양의 치료
TW202237648A (zh) 2020-11-18 2022-10-01 美商開拓免疫醫療公司 抗marco抗體及其用途

Also Published As

Publication number Publication date
US20260172900A1 (en) 2026-06-18
JP2023549555A (ja) 2023-11-27
WO2022109178A9 (en) 2023-07-13
WO2022109178A1 (en) 2022-05-27
US11572407B2 (en) 2023-02-07
TW202237648A (zh) 2022-10-01
IL302874A (en) 2023-07-01
MX2023005841A (es) 2023-08-16
US12378311B2 (en) 2025-08-05
AU2021382658A1 (en) 2023-07-06
EP4247419A4 (en) 2024-11-06
US20220153832A1 (en) 2022-05-19
EP4247419A1 (en) 2023-09-27
US20240084000A1 (en) 2024-03-14
KR20230121759A (ko) 2023-08-21

Similar Documents

Publication Publication Date Title
JP7069261B2 (ja) Cd73特異的結合分子及びその使用
US10604576B2 (en) Antibodies and immunocytokines
US12378311B2 (en) Anti-MARCO antibodies and uses thereof
WO2022256563A1 (en) Anti-ccr8 antibodies and uses thereof
JP7596263B2 (ja) 4-1bb及び腫瘍関連抗原に結合する抗体構築物ならびにその使用
KR20230164243A (ko) Icos에 대한 항체
JP7759996B2 (ja) 抗trem1抗体及び関連方法
CA3216324A1 (en) Anti-siglec compositions and uses thereof
EP3941940A1 (en) Antibodies having specificity for btn2 and uses thereof
EA052033B1 (ru) Антитела к marco и их применение
HK40096227A (zh) 抗marco抗体和其用途
CN116635073A (zh) 抗marco抗体和其用途
HK40065337A (en) Anti-trem1 antibodies and related methods

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241108

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241108

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241108

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251114

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251114

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251117

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251117

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251117

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260112

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260112

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260112

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260113